Together we will beat cancer


New test could help select the best treatment for bowel cancer patients

A new test could help patients with advanced bowel cancer get the best treatment for their disease.

Read More

Skin rash predicts survival benefit from latest lung cancer drug

Elderly patients with advanced non small cell lung cancer (NSCLC) who developed a rash within 28 days of receiving the targeted drug erlotinib (Tarceva) survived on average 6.2 months, compared to 4.1 months for patients who were given a placebo, results from a major phase III Cancer Research UK-funded trial show today (Tuesday).

Read More

New Guide Can Predict Patients’ Survival

A new way of predicting how long terminally ill cancer patients have to live, has been devised by Cancer Research UK-funded research.

Read More

New funding for British research into cancer care

Two grants have been awarded from a programme of nearly Ј5 million to boost research into supportive and palliative care for British cancer patients.

Read More